Michael G. Grey - May 3, 2023 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
May 3, 2023
Transactions value $
-$366,135
Form type
4
Date filed
5/4/2023, 09:58 PM
Previous filing
May 2, 2023
Next filing
May 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $42.9K +14.6K $2.94 14.6K May 3, 2023 Direct
transaction MIRM Common Stock Sale -$409K -14.6K -100% $28.00 0 May 3, 2023 Direct F1
holding MIRM Common Stock 289K May 3, 2023 By The Grey Family Trust dated November 12,1999
holding MIRM Common Stock 93.8K May 3, 2023 By The Grey 2018 Irrevocable Children's Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Options Exercise $0 -14.6K -3.9% $0.00 360K May 3, 2023 Common Stock 14.6K $2.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted August 30, 2022.
F2 1/4th of the shares vest one year after November 5, 2018, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.